Establishment Labs Reports the US FDA’s Approval of Motiva Implants
Shots:
- The US FDA approves Motiva SmoothSilk Ergonomix & Motiva SmoothSilk Round breast implants for primary & revision breast augmentation, based on Motiva US IDE study
- Study showed 92.4% patient compliance after 3yrs. post-implantation and low complication rates incl. 0.5% capsular contracture, 0.6% rupture, 0.7% breast pain & 0.9% infection in the primary augmentation cohort. Reoperations incl. implant size change was reported at 6.1% & any complication incl. reoperations were reported at 8.4%
- Motiva SmoothSilk Round and Ergonomix Implants consists of SmoothSilk surface for biocompatibility & low inflammation
Ref: Establishment Labs | Image: Establishment Labs
Related News:- Johnson & Johnson Reports the Acquisition of Shockwave Medical to Strengthen its MedTech Cardiovascular Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
